As COVID-19 therapies get emergency-use green lights, the Biden administration must organize a therapeutic review board to help identify what’s working and what’s not.

Two new medications for treating a rare and deadly neuromuscular disease have high prices and questionable efficacies, say scientists.

Although scientists debate the ethics of deliberately infecting volunteers with SARS-CoV-2, plenty of consenting participants have been exposed to all sorts of pathogens in prior trials.

Researchers say the popularity of convalescent plasma makes it more difficult to gather high-quality data on its efficacy.

Screens of hundreds of drug excipients reveal that some can interact with biological targets, contradicting their FDA categorization as inert.

Vaccine experts divided on whether that level of protection is too low or too demanding.

Hydroxychloroquine and chloroquine, once thought to be promising COVID-19 treatments, come with serious heart risks.

Kennedy, who succumbed to COVID-19, served as commissioner of the FDA and editor-in-chief of Science, and is credited with helping to transform Stanford into a top research university.

Abbott’s ID NOW test missed the most positive samples among five products given the green light by the FDA to use during the pandemic.